Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics
Abstract This study employed physiologically based pharmacokinetic (PBPK) modelling to compare the extent of foetal exposure between oral and long-acting injectable (LAI) aripiprazole and olanzapine. Adult and pregnancy PBPK models were developed and validated with relevant clinical data. Relevant i...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Women's Health |
| Online Access: | https://doi.org/10.1038/s44294-025-00077-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850154849121861632 |
|---|---|
| author | Philip Bediako-Kakari Mariella Monyo Shakir Atoyebi Adeniyi Olagunju |
| author_facet | Philip Bediako-Kakari Mariella Monyo Shakir Atoyebi Adeniyi Olagunju |
| author_sort | Philip Bediako-Kakari |
| collection | DOAJ |
| description | Abstract This study employed physiologically based pharmacokinetic (PBPK) modelling to compare the extent of foetal exposure between oral and long-acting injectable (LAI) aripiprazole and olanzapine. Adult and pregnancy PBPK models were developed and validated with relevant clinical data. Relevant indices of foetal exposure during pregnancy were predicted from concentration-time data at steady-state dosing for both oral and LAI formulations. Foetal Cmax for aripiprazole was 59–78% higher with LAI than oral, and 68–181% higher with LAI olanzapine than the oral formulation. Predicted cord:maternal ratios (range) were 0.59–0.69 for oral aripiprazole and 0.61–0.66 for LAI aripiprazole, 0.34–0.64 for oral olanzapine and 0.89–0.96 for LAI olanzapine. Also, cumulative foetal exposure over 28 days from oral formulations were generally predicted to be lower compared with their therapeutic-equivalent LAI. As in utero foetal exposure to maternal drugs does not necessarily translate to risk, these data should be interpreted in a broader context that includes benefit-risk assessments. |
| format | Article |
| id | doaj-art-7f25704a7e76439fbe809bbf830021f8 |
| institution | OA Journals |
| issn | 2948-1716 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Women's Health |
| spelling | doaj-art-7f25704a7e76439fbe809bbf830021f82025-08-20T02:25:09ZengNature Portfolionpj Women's Health2948-17162025-05-013111010.1038/s44294-025-00077-9Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychoticsPhilip Bediako-Kakari0Mariella Monyo1Shakir Atoyebi2Adeniyi Olagunju3School of Biosciences, University of LiverpoolSchool of Biosciences, University of LiverpoolCentre of Excellence for Long-acting Therapeutics, University of LiverpoolCentre of Excellence for Long-acting Therapeutics, University of LiverpoolAbstract This study employed physiologically based pharmacokinetic (PBPK) modelling to compare the extent of foetal exposure between oral and long-acting injectable (LAI) aripiprazole and olanzapine. Adult and pregnancy PBPK models were developed and validated with relevant clinical data. Relevant indices of foetal exposure during pregnancy were predicted from concentration-time data at steady-state dosing for both oral and LAI formulations. Foetal Cmax for aripiprazole was 59–78% higher with LAI than oral, and 68–181% higher with LAI olanzapine than the oral formulation. Predicted cord:maternal ratios (range) were 0.59–0.69 for oral aripiprazole and 0.61–0.66 for LAI aripiprazole, 0.34–0.64 for oral olanzapine and 0.89–0.96 for LAI olanzapine. Also, cumulative foetal exposure over 28 days from oral formulations were generally predicted to be lower compared with their therapeutic-equivalent LAI. As in utero foetal exposure to maternal drugs does not necessarily translate to risk, these data should be interpreted in a broader context that includes benefit-risk assessments.https://doi.org/10.1038/s44294-025-00077-9 |
| spellingShingle | Philip Bediako-Kakari Mariella Monyo Shakir Atoyebi Adeniyi Olagunju Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics npj Women's Health |
| title | Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics |
| title_full | Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics |
| title_fullStr | Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics |
| title_full_unstemmed | Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics |
| title_short | Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics |
| title_sort | comparative modelling of foetal exposure to maternal long acting injectable versus oral daily antipsychotics |
| url | https://doi.org/10.1038/s44294-025-00077-9 |
| work_keys_str_mv | AT philipbediakokakari comparativemodellingoffoetalexposuretomaternallongactinginjectableversusoraldailyantipsychotics AT mariellamonyo comparativemodellingoffoetalexposuretomaternallongactinginjectableversusoraldailyantipsychotics AT shakiratoyebi comparativemodellingoffoetalexposuretomaternallongactinginjectableversusoraldailyantipsychotics AT adeniyiolagunju comparativemodellingoffoetalexposuretomaternallongactinginjectableversusoraldailyantipsychotics |